WO2024084496A1 - Pharmaceutical compositions comprising acalabrutinib maleate - Google Patents
Pharmaceutical compositions comprising acalabrutinib maleate Download PDFInfo
- Publication number
- WO2024084496A1 WO2024084496A1 PCT/IN2023/050921 IN2023050921W WO2024084496A1 WO 2024084496 A1 WO2024084496 A1 WO 2024084496A1 IN 2023050921 W IN2023050921 W IN 2023050921W WO 2024084496 A1 WO2024084496 A1 WO 2024084496A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acalabrutinib
- maleate
- tablet composition
- composition
- iii
- Prior art date
Links
- JWEQLWMZHJSMEC-AFJTUFCWSA-N 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide (Z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12 JWEQLWMZHJSMEC-AFJTUFCWSA-N 0.000 title claims abstract description 88
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 74
- 239000007916 tablet composition Substances 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 34
- 239000011248 coating agent Substances 0.000 claims description 27
- 238000000576 coating method Methods 0.000 claims description 27
- 239000000314 lubricant Substances 0.000 claims description 26
- 239000007884 disintegrant Substances 0.000 claims description 25
- 239000003085 diluting agent Substances 0.000 claims description 24
- 238000002156 mixing Methods 0.000 claims description 23
- 239000007888 film coating Substances 0.000 claims description 22
- 238000009501 film coating Methods 0.000 claims description 22
- 230000008569 process Effects 0.000 claims description 22
- 239000011230 binding agent Substances 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 17
- 229920000881 Modified starch Polymers 0.000 claims description 13
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 12
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 230000001050 lubricating effect Effects 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 238000009490 roller compaction Methods 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 229940069328 povidone Drugs 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 238000007909 melt granulation Methods 0.000 claims description 3
- 238000007907 direct compression Methods 0.000 claims description 2
- 238000007908 dry granulation Methods 0.000 claims description 2
- 238000005550 wet granulation Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 45
- 238000004519 manufacturing process Methods 0.000 abstract description 9
- 229940125814 BTK kinase inhibitor Drugs 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 description 57
- 238000002360 preparation method Methods 0.000 description 18
- 239000000463 material Substances 0.000 description 15
- 239000002552 dosage form Substances 0.000 description 13
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 description 11
- 229950009821 acalabrutinib Drugs 0.000 description 11
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000005469 granulation Methods 0.000 description 6
- 230000003179 granulation Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 description 5
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- -1 spheroids Substances 0.000 description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000004408 titanium dioxide Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 229920002301 cellulose acetate Polymers 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 3
- 229960005191 ferric oxide Drugs 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004191 allura red AC Substances 0.000 description 2
- 235000012741 allura red AC Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229920001531 copovidone Polymers 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 238000003618 dip coating Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 2
- 239000004174 erythrosine Substances 0.000 description 2
- 229940011411 erythrosine Drugs 0.000 description 2
- 235000012732 erythrosine Nutrition 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000004172 quinoline yellow Substances 0.000 description 2
- 229940051201 quinoline yellow Drugs 0.000 description 2
- 235000012752 quinoline yellow Nutrition 0.000 description 2
- IZMJMCDDWKSTTK-UHFFFAOYSA-N quinoline yellow Chemical compound C1=CC=CC2=NC(C3C(C4=CC=CC=C4C3=O)=O)=CC=C21 IZMJMCDDWKSTTK-UHFFFAOYSA-N 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000004149 tartrazine Substances 0.000 description 2
- 229960000943 tartrazine Drugs 0.000 description 2
- 235000012756 tartrazine Nutrition 0.000 description 2
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- XZAATUBTUPPERZ-UHFFFAOYSA-N 4-[8-amino-3-[4-(but-2-ynoylamino)butanoyl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide Chemical compound CC#CC(=O)NCCCC(=O)C1=NC(=C2N1C=CN=C2N)C1=CC=C(C=C1)C(=O)NC1=NC=CC=C1 XZAATUBTUPPERZ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940051164 ferric oxide yellow Drugs 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 238000009478 high shear granulation Methods 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000002346 layers by function Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009476 low shear granulation Methods 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008185 minitablet Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229940050929 polyethylene glycol 3350 Drugs 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- WQQPDTLGLVLNOH-UHFFFAOYSA-M sodium;4-hydroxy-4-oxo-3-sulfobutanoate Chemical class [Na+].OC(=O)CC(C([O-])=O)S(O)(=O)=O WQQPDTLGLVLNOH-UHFFFAOYSA-M 0.000 description 1
- VJLLAIFTNPXQCJ-BUFQOAPZSA-M sodium;octadecanoic acid;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O VJLLAIFTNPXQCJ-BUFQOAPZSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Abstract
The present invention relates to pharmaceutical compositions comprising a Bruton tyrosine kinase (BTK) inhibitor. More particularly, the present invention relates to a composition comprising Acalabrutinib maleate and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
Description
PHARMACEUTICAL COMPOSITIONS COMPRISING ACALABRUTINIB MALEATE
Field of the invention
The present invention relates to pharmaceutical compositions comprising a Bruton tyrosine kinase (BTK) inhibitor. More particularly, the present invention relates to a composition comprising Acalabrutinib maleate and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
Background of the invention
Background description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.
Acalabrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK). The chemical name for Acalabrutinib is 4-{8-amino-3-[(2S)-l-(but-2-ynoyl) pyrrolidin-2- yl]imidazo[ 1 ,5-a]pyrazin- 1 -yl) } -N-(pyridine-2-yl)benzamide.
Acalabrutinib maleate is approved in the form of tablets and marketed by AstraZeneca under the brand name CALQUENCE®. The approved tablets contain Acalabrutinib maleate monohydrate equivalent to 100 mg of acalabrutinib free base.
Acalabrutinib tablets are indicated for the treatment of Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
Acalabrutinib is a small-molecule inhibitor of BTK. Acalabrutinib and its active metabolite, ACP-5862, form a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity.
CALQUENCE® (Acalabrutinib) tablets for oral administration contains 100 mg acalabrutinib (equivalent to 129 mg of acalabrutinib maleate) and the following inactive ingredients: Low-substituted hydroxypropyl cellulose, Mannitol,
Microcrystalline cellulose, Sodium stearyl fumarate, The tablet coating contains Copovidone, Ferric oxide yellow, Ferric oxide red, Hypromellose, Medium-chain triglycerides, Polyethylene glycol 3350, Purified water and titanium dioxide.
WO 2021/255246 Al discloses solid pharmaceutical dosage forms wherein the dosage form comprises: acalabrutinib maleate in an amount from about 15% to about 55% by weight of the dosage form; at least one diluent in an amount from about 10% to about 70% by weight of the dosage form; at least one disintegrant in an amount from about 0.5% to about 15% by weight of the dosage form; and at least one lubricant in an amount from about 0.25% to about 4% by weight of the dosage form; and wherein the sum of the individual amounts equals 100% of the total weight of the dosage form.
All publications herein are incorporated by reference to the same extent as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Where a definition or use of a term in an incorporated reference is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply. The above prior art reference discloses solid dosage form comprising specific percentages of Acalabrutinib maleate, diluent, disintegrant and a lubricant. Still, there exists a need to develop an alternative solid dosage form comprising Acalabrutinib maleate which have comparable dissolution properties, content uniformity, stability and equivalent bioavailability w.r.t commercialized Acalabrutinib tablet dosage form.
Objective of the invention
The main objective of the present invention relates to a pharmaceutical composition comprising Acalabrutinib maleate.
The present invention also relates to a tablet composition comprising Acalabrutinib maleate and one or more pharmaceutically acceptable excipients.
The present invention also relates to a process for the preparation of tablet composition comprising Acalabrutinib maleate and one or more pharmaceutically acceptable excipients having comparable dissolution properties, content uniformity, stability and equivalent bioavailability w.r.t commercialized Acalabrutinib tablet dosage form.
Summary of the invention
Accordingly, the present invention provides a pharmaceutical composition comprising Acalabrutinib maleate and one or more pharmaceutically acceptable excipients.
The present invention also relates to a pharmaceutical composition comprising Acalabrutinib maleate and one or more pharmaceutically acceptable excipients, wherein the composition is free of a disintegrant.
The present invention also relates to a tablet composition comprising Acalabrutinib maleate and one or more pharmaceutically acceptable excipients.
The present invention also relates to a tablet composition comprising Acalabrutinib maleate and one or more pharmaceutically acceptable excipients, wherein the composition is free of a disintegrant.
The present invention also relates to a process for the preparation of tablet composition comprising Acalabrutinib maleate and one or more pharmaceutically acceptable excipients.
The present invention also relates to a process for the preparation of tablet composition comprising Acalabrutinib maleate and one or more pharmaceutically acceptable excipients, wherein the composition is free of a disintegrant.
Detailed description of the invention
The following is a detailed description of embodiments of the present invention. The embodiments are in such detail as to clearly communicate the invention. However, the amount of detail offered is not intended to limit the
anticipated variations of embodiments; on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the present invention as defined by the appended claims.
Unless the context requires otherwise, throughout the specification which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense that is as “including, but not limited to.” It is to be appreciated that the terms "comprising", "comprises" and "comprised of" as used herein includes the terms "consisting of", "consists" and "consists of" within their meaning.
Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
As used in the description herein and throughout the claims that follow, the meaning of “a,” “an,” and “the” includes plural reference unless the context clearly dictates otherwise. Also, as used in the description herein, the meaning of “in” includes “in” and “on” unless the context clearly dictates otherwise.
In some embodiments, the numbers expressing quantities of ingredients, properties such as concentration, and so forth, used to describe and claim certain embodiments of the invention are to be understood as being modified in some instances by the term “about.” Accordingly, in some embodiments, the numerical parameters set forth in the written description are approximations that can vary depending upon the desired properties sought to be obtained by a particular embodiment. In some embodiments, the numerical parameters should be construed in
light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of some embodiments of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as practicable.
The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein.
The headings and abstract of the invention provided herein are for convenience only and do not interpret the scope or meaning of the embodiments.
All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. “such as”) provided with respect to certain embodiments herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
The following discussion provides many example embodiments of the inventive subject matter. Although each embodiment represents a single combination of inventive elements, the inventive subject matter is considered to include all possible combinations of the disclosed elements. Thus if one embodiment comprises elements A, B, and C, and a second embodiment comprises elements B and D, then the inventive subject matter is also considered to include other remaining combinations of A, B, C, or D, even if not explicitly disclosed.
Various terms as used herein are shown below. To the extent a term used in a claim is not defined below, it should be given the broadest definition persons in the pertinent art have given that term as reflected in printed publications and issued patents at the time of filing.
The term “active ingredient” or “active agent” or “drug” used interchangeably, is defined to mean active drug, that induce a desired pharmacological or physiological effect.
The term “pharmaceutically acceptable” as used herein means that which is useful in preparing a pharmaceutical composition that is generally safe and non-toxic.
By the term “solid dosage form” or “dosage form” or “composition” as used herein refers to a solid dosage form suitable for administration, such as a tablet, capsule, spheroids, mini-tablets, pellets, granules, pills and the like.
As used in the specification and the appended claims, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. Thus for example, reference to “a method” includes one or more methods, and/or steps of the type described herein and/or which will become apparent to those persons skilled in the art upon reading this disclosure so forth.
The term "including" is used to mean "including but not limited to". "Including" and "including but not limited to" are used interchangeably.
The term “excipient” as used herein refers to a components that can be added in the composition, that are physiologically tolerable and do not typically produce allergic or similar untoward reaction. The excipient also provides improved stability and therapeutic enhancement to the composition. The excipients added to the composition to facilitate manufacture, enhance stability, control release, enhance product characteristics, enhance bioavailability, enhance patient acceptability, etc.
The term “excipient” and “pharmaceutically acceptable excipient” shall be used interchangeably.
Ratios, concentrations, amounts, and other numerical data may be presented herein in a range format. It is to be understood that such range format is used merely for convenience and brevity and should be interpreted flexibly to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. For example, a weight percentage range of 0.001 to 50% (w/w) should be interpreted to include not only the explicitly recited limits of 0.01% (w/w) to 45% (w/w) but also to include sub-ranges, such as 0.05% to 40% (w/w), 0.1% to 7% (w/w) and so forth, as well as individual amounts, including fractional amounts, within the specified ranges, such as 0.022%, 0.01%, 0.58%, 0.9%, 1.39% , 5.4%, 22.6% for example.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the disclosure, the preferred methods, and materials are now described. All publications mentioned herein are incorporated herein by reference.
In another embodiment, the present invention also relates to a pharmaceutical composition comprising Acalabrutinib maleate and one or more pharmaceutically acceptable excipients, wherein the composition is free of a disintegrant.
In one embodiment, the present invention further relates to a tablet composition comprising Acalabrutinib maleate and one or more pharmaceutically acceptable excipients.
In another embodiment, the present invention also relates to a process for preparing a tablet composition comprising Acalabrutinib maleate and one or more pharmaceutically acceptable excipients.
In another embodiment, the present invention also relates to a tablet composition comprising Acalabrutinib maleate and one or more pharmaceutically acceptable excipients, wherein the composition is free of a disintegrant.
In another embodiment, the present invention also relates to a process for the preparation of tablet composition comprising Acalabrutinib maleate and one or more pharmaceutically acceptable excipients, wherein the composition is free of a disintegrant.
In another embodiment, the tablet composition according to the present invention is an immediate release tablet composition.
In one embodiment of the present invention, Acalabrutinib maleate may be present in crystalline form or amorphous form.
In another embodiment of the present invention, Acalabrutinib maleate may be present in crystalline form.
As used herein, the term “% w/w” refers to the weight of the component based on the total weight of a composition comprising the component.
In another embodiment of the present invention, the composition comprises Acalabrutinib maleate in an amount of 20-80% w/w, preferably 30-60 %w/w and most preferably 30-50% w/w of the composition.
In another embodiment of the present invention, the composition comprises Acalabrutinib maleate in an amount of 20-80% w/w, preferably 30-60 %w/w and most preferably 30-50% w/w of the composition. “Pharmaceutically acceptable excipient/s” are the components added to pharmaceutical formulation to facilitate manufacture, enhance stability, control release, enhance product characteristics, enhance bioavailability, enhance patient acceptability, etc.
In another embodiment, the composition according to the present invention further comprises one or more pharmaceutically acceptable excipients which include but not limited to fillers/diluents, binders, surfactants, glidants and lubricants. These excipients may be present intragranularly or extragranularly.
In another embodiment, the composition according to the present invention is completely “free of a disintegrant” and the pharmaceutically acceptable excipient does not include a disintegrant.
It is to be understood herein that the expression “free of a disintegrant” is meant to characterize the pharmaceutical composition as not comprising a disintegrant type substance(s) or compound(s). On the other hand, it is to be understood herein, that the above expression with respect to the absence of a disintegrant, do not necessarily exclude a substance(s) or compound(s) having a (known) disintegrant function but which may also be exploited so as to effectively take advantage of a different excipient function (e.g. as a binder, diluent, etc.) i.e. in other words such a dual purpose substance(s) or compound(s) may yet be present so as to effectively take advantage of such different excipient function (e.g. as a binder element, diluent element, etc.).
Fillers/diluents according to the present invention include but not limited to microcrystalline cellulose, silicified microcrystalline cellulose, lactose monohydrate, lactose anhydrous, fructose, maltose, trehalose, dextrose, polydextrose, dextrates, dextrins, isomalt, mannitol, maltitol, xylitol, maltodextrin, lactitol, sorbitol, erythritol, inulin, starch, pregelatinized starch, partially pregelatinized starch, sucrose, calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, magnesium carbonate, magnesium oxide, sodium bicarbonate, sodium carbonate, sodium chloride, cellulose acetate, ethyl cellulose, cellulose powdered, kaolin and the like or combinations thereof. The fillers/diluents can be used in the range of about 0-
90% w/w, preferably 10-80% w/w and more preferably 30-60% w/w of the composition.
Binders according to the present invention include but not limited to hydroxypropyl methylcellulose (Hypromellose), hydroxypropyl cellulose, gelatin, ethyl cellulose, polyvinyl alcohol, pregelatinized starch, partially pregelatinized starch, carboxymethyl cellulose, sodium alginate, polyvinyl pyrrolidones (povidone), copovidone, microcrystalline cellulose, gelatin, polymethacrylates, polyethylene glycols (PEG), Poly(vinyl caprolactam-co-vinyl acetate-ethylene glycol) graft polymer (SOLUPLUS®), poloxamers, polyethylene oxide, acrylate based copolymers and the like or combinations thereof. The binder can be used in the range of about 0- 15% w/w of the composition.
Surfactants according to the present invention may be selected from anionic, cationic or non- ionic surface-active agents or surfactants. Suitable anionic surfactants include but not limited to carboxylate, sulfonate, and sulfate ions such as sodium lauryl sulfate (SLS), sodium laurate, dialkyl sodium sulfosuccinates particularly bis- (2-ethylhexyl) sodium sulfosuccinate, sodium stearate, potassium stearate, sodium oleate and the like. Suitable cationic surfactants include but not limited to those containing long chain cations, such as benzalkonium chloride, bis-2- hydroxyethyl oleyl amine or the like. Suitable non-ionic surfactants include but not limited to polyoxyethylene sorbitan fatty acid esters (polysorbates), fatty alcohols such as lauryl, cetyl and stearyl alcohols; glyceryl esters such as the naturally occurring mono-, di-, and tri-glycerides; fatty acid esters of fatty alcohols; polyglycolized glycerides such as gelucire; polyoxyethylene-poly oxypropylene block co-polymer such as Poloxamer and other alcohols such as propylene glycol, polyethylene glycol. The surfactant can be used in the range of about 0-20% w/w of the composition.
Glidants according to the present invention include but not limited to silica, colloidal silicon dioxide, talc and magnesium silicate and mixtures thereof. The
glidants can be used in the range of 0-10% w/w, preferably 0.5-5% w/w of the composition.
Lubricants according to the present invention include but not limited to stearic acid, magnesium stearate, calcium stearate, sodium stearyl fumarate, talc, zinc stearate, glyceryl mono fatty acid, glyceryl monostearate, glyceryl dibehenate, glyceryl palmito stearic ester, hydrogenated castor oil and mixtures thereof. The Lubricants can be used in the range of 0-10% w/w, preferably 0.5-5% w/w of the composition.
In another embodiment, the present invention relates to a tablet composition comprising:
(i) Acalabrutinib maleate,
(ii) one or more diluents,
(iii) one or more lubricants,
(iv) optionally one or more binders,
(v) optionally one or more surfactants, and wherein the tablet composition is free of a disintegrant.
In another embodiment, the present invention relates to a tablet composition comprising:
(i) Acalabrutinib maleate
(ii) one or more diluents,
(iii) one or more lubricants,
(iv) optionally one or more binders, and wherein the tablet composition is free of a disintegrant.
In another embodiment, the present invention relates to a tablet composition comprising:
(i) 30-60% w/w of Acalabrutinib maleate,
(ii) 30-60% w/w of one or more diluents,
(iii) 0.5-5% w/w of one or more lubricants, and
(iv) 0-15% w/w of one or more binders,
wherein the tablet composition is free of a disintegrant.
In another embodiment, the present invention relates to a tablet composition, wherein the tablet composition is further coated with a film coating composition.
In another embodiment, the present invention relates to a tablet composition comprising:
(i) Acalabrutinib maleate,
(ii) one or more diluents,
(iii) one or more lubricants,
(iv) optionally one or more binders,
(v) optionally one or more surfactants,
(vi) a film coating over the tablet composition, and wherein the tablet composition is free of a disintegrant.
In another embodiment, the present invention relates to a tablet composition comprising:
(i) Acalabrutinib maleate,
(ii) one or more diluents,
(iii) one or more lubricants,
(iv) optionally one or more binders,
(vi) a film coating over the tablet composition, and wherein the tablet composition is free of a disintegrant.In another embodiment, the present invention relates to a tablet composition consisting of:
(i) 30-60% w/w of Acalabrutinib maleate,
(ii) 30-60% w/w of a diluent, and
(iii) 0.5-5% w/w of a lubricant, wherein the tablet composition is free of a disintegrant.
In another embodiment, the present invention relates to a tablet composition consisting of:
(i) 30-60% w/w of Acalabrutinib maleate,
(ii) 30-60% w/w of a diluent,
(iii) 0.5-5% w/w of a lubricant, and
(iv) a film coating over the tablet composition, wherein the tablet composition is free of a disintegrant.
In another embodiment, the present invention relates to a tablet composition, wherein: one or more diluents are selected from pregelatinized starch, mannitol, microcrystalline cellulose, silicified microcrystalline cellulose and lactose; one or more lubricants are selected from sodium stearyl fumarate and magnesium stearate; and one or more binders are selected from povidone, hydroxypropyl cellulose and hydroxypropyl methylcellulose.
In another embodiment, the present invention relates to a tablet composition comprising:
(i) 30-60% w/w of Acalabrutinib maleate,
(ii) 30-60% w/w of one or more diluents selected from pregelatinized starch, mannitol, microcrystalline cellulose, silicified microcrystalline cellulose and lactose,
(iii) 0.5-5% w/w of one or more lubricants selected from sodium stearyl fumarate and magnesium stearate, and
(iv) 0-15% w/w of one or more binders selected from povidone, hydroxypropyl cellulose and hydroxypropyl methylcellulose.
In another embodiment, the present invention relates to a tablet composition consisting of:
(i) 30-60% w/w of Acalabrutinib maleate
(ii) 30-60% w/w of pregelatinized starch,
(iii) 0.5-5% w/w of sodium stearyl fumarate, and
(iv) a film coating over the tablet composition, wherein the tablet composition is free of a disintegrant.
In another embodiment, the present invention relates to a process for the preparation of pharmaceutical composition, comprising the steps of:
(i) blending Acalabrutinib maleate with one or more pharmaceutically acceptable excipients,
(ii) formulating the blend of step (i) into suitable dosage form.
In another embodiment, the present invention relates to a process for the preparation of pharmaceutical composition, comprising the steps of:
(i) blending Acalabrutinib maleate with one or more pharmaceutically acceptable excipients,
(ii) optionally, lubricating the blended material of step (i) with a lubricant, and
(iii) preparing the lubricated material of step (ii) into a suitable dosage form.
In another embodiment, the present invention relates to a process for the preparation of pharmaceutical composition, comprising the steps of:
(i) blending Acalabrutinib maleate with one or more pharmaceutically acceptable excipients,
(ii) optionally, lubricating the blended material of step (i) with a lubricant, and
(iii) compressing the lubricated material of step (ii) into tablets.
In another embodiment, the present invention relates to a process for the preparation of pharmaceutical composition, comprising the steps of:
(i) blending Acalabrutinib maleate with one or more pharmaceutically acceptable excipients,
(ii) optionally, lubricating the blended material of step (i) with a lubricant, and
(iii) compressing the lubricated material of step (ii) into tablets, and
(iv) optionally coating the tablets obtained in step (iii) with a film coating composition.
In another embodiment, the present invention relates to a process for the preparation of pharmaceutical composition, comprising the steps of:
(i) blending Acalabrutinib maleate with one or more pharmaceutically acceptable excipients,
(ii) optionally, lubricating the blended material of step (i) with a lubricant, and
(iii) compressing the lubricated material of step (ii) into tablets, and
(iv) coating the tablets obtained in step (iii) with a film coating composition.
In another embodiment, the present invention relates to a process for the preparation of pharmaceutical composition, comprising the steps of:
(i) blending Acalabrutinib maleate with one or more pharmaceutically acceptable excipients,
(ii) granulating the blend of step (i),
(iii) blending the granules of step (ii) with one or more pharmaceutically acceptable excipients, and
(iv) compressing the blend of step (iii) into tablets.
In another embodiment, the present invention relates to a process for the preparation of pharmaceutical composition, comprising the steps of:
(i) blending Acalabrutinib maleate with one or more pharmaceutically acceptable excipients,
(ii) granulating the blend of step (i),
(iii) blending the granules of step (ii) with one or more pharmaceutically acceptable excipients,
(iv) compressing the blend of step (iii) into tablets, and
(v) optionally coating the tablets obtained in step (iv) with a film coating composition.
In another embodiment, the present invention relates to a process for the preparation of pharmaceutical composition, comprising the steps of:
(i) blending Acalabrutinib maleate with one or more pharmaceutically acceptable excipients,
(ii) granulating the blend of step (i),
(iii) blending the granules of step (ii) with one or more pharmaceutically acceptable excipients,
(iv) compressing the blend of step (iii) into tablets, and
(v) coating the tablets obtained in step (iv) with a film coating composition.
In another embodiment, the present invention relates to a process for the preparation of tablet composition, comprising the steps of:
(i) blending Acalabrutinib maleate with one or more diluents,
(ii) granulating the blend of step (i),
(iii) blending the granules of step (ii) with one or more lubricants,
(iv) compressing the blend of step (iii) into tablets, and
(v) coating the tablets obtained in step (iv) with a film coating composition.
In another embodiment, the present invention relates to a process for the preparation of tablet composition, comprising the steps of:
(i) blending Acalabrutinib maleate with one or more diluents,
(ii) lubricating the blend of step (i) with one or more lubricants,
(iii) compressing the blend of step (ii) into tablets, and
(iv) coating the tablets obtained in step (iii) with a film coating composition.
In another embodiment, the present invention relates to a process for the preparation of tablet composition, comprising the steps of:
(i) blending Acalabrutinib maleate with pregelatinized starch,
(ii) granulating the blend of step (i) using roller compaction,
(iii) lubricating the granules of step (ii) with sodium stearyl fumarate,
(iv) compressing the lubricated blend of step (iii) into tablets, and
(v) coating the tablets obtained in step (iv) with a film coating composition.
In another embodiment, the present invention relates to a process for the preparation of pharmaceutical composition, comprising the steps of:
(i) blending Acalabrutinib maleate with one or more pharmaceutically acceptable excipients,
(iii) filling the blend of step (i) into capsules.
In another embodiment, the present invention relates to a process for the preparation of pharmaceutical composition, comprising the steps of:
(i) blending Acalabrutinib maleate with one or more pharmaceutically acceptable excipients,
(ii) lubricating the blended material of step (i) with a lubricant, and
(iii) filling the lubricated material of step (ii) into capsules.
In another embodiment, the present invention relates to a process for the preparation of pharmaceutical composition, comprising the steps of:
(i) blending Acalabrutinib maleate with one or more pharmaceutically acceptable excipients,
(ii) granulating the blend of step (i),
(iii) blending the granules of step (ii) with one or more pharmaceutically acceptable excipients, and
(iii) filling the blend of step (iii) into capsules.
In another embodiment, the pharmaceutical composition according to the present invention is in the form of tablets, capsules, granules, powder, pellets and sachets.
In another preferred embodiment, the pharmaceutical composition according to the present invention is in the form of tablets.
In another embodiment, the blend is formulated into a suitable dosage form like tablets or capsules using different techniques which are well known in the prior art.
In another embodiment, the compositions of the present invention may be prepared using any method known in the art, but are not limited to wet granulation, melt granulation, dry granulation, roller compaction, solid dispersion, encapsulation and direct compression.In another embodiment, the granulation can be done using one pharmaceutically acceptable excipient, a binder, which can be added to the drug substance in a dissolved state (e.g. in an aqueous/non-aqueous solution) or in a powder form and then granulated by adding a granulation liquid. A combination of more than one binder can be used.
In another embodiment, the solvents used for granulation process may be selected from water, isopropyl alcohol, methanol, ethanol, methylene chloride or combination thereof.
In another embodiment, the granulation can be done using any method known in the art, but are not limited to fluidized bed granulation, high-shear granulation, low shear granulation, spray granulation, melt granulation and hot melt extrusion.
The pharmaceutical composition may be further film coated with functional or non functional layer. The coating may be selected from amongst one or more of those suitable coating materials known in the art. For example, the coating material can be Opadry or Opadry AMB. Coating may be performed by applying one or more film forming polymers, with or without other pharmaceutically inert excipients, as a solution/suspension using any conventional coating technique known in the art, such as spray coating in a conventional coating pan or fluidized bed processor; or dip coating.
Coloring agent may be selected from FDA approved colorants such as Iron Oxide, Lake of Tartrazine, Allura Red, Lake of Quinoline Yellow, Lake of Erythrosine, Titanium Dioxide and the like.
The composition according to the present invention may be uncoated or optionally coated with functional coating, film coating, moisture barrier coating or a protective coating composition. The coating may be selected from amongst one or more of those suitable coating materials known in the art. Coating may be performed by applying one or more film forming polymers, with or without other pharmaceutically inert excipients, as a solution/suspension using any conventional coating technique known in the art, such as spray coating in a conventional coating pan or fluidized bed processor or dip coating.
The amount of the film coating may be about 1 to about 10% w/w, preferably, about 1 to about 3% w/w, of the total composition. Any of a variety of film coatings can be used in the present composition. Suitable film coating may include but not limited to polymers, plasticizers, pigments, opacifiers, glidants, binders, antitacking agents, antifoaming agents, surfactants, fillers, extenders, coloring agents and the like.
Examples of film-forming polymers include ethylcellulose, hydroxypropyl methylcellulose, polyvinyl alcohol (PVA), hydroxypropylcellulose, methylcellulose, carboxymethyl cellulose, hydroxymethylcellulose, hydroxyethylcellulose, cellulose acetate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate; waxes such as polyethylene glycol; methacrylic acid polymers such as Eudragit ® RL and RS; and the like. Alternatively, commercially available coating compositions comprising film forming polymers marketed under various trade names, such as Opadry® may also be used for coating the tablets. The coating can be obtained as a dry blend concentrate.
The film coating may also optionally include a plasticizer such as triacetin, propylene glycol, diethyl phthalate, tributyl sebacate or polyethylene glycol (PEG), preferably PEG; and an anti-adherent or glidant such as talc, fumed silica or magnesium stearate, an opacifying agent such as titanium dioxide.
Coloring agent may be selected from FDA approved colorants such as Iron Oxide, Lake of Tartrazine, Allura Red, Lake of Quinoline Yellow, Lake of Erythrosine, titanium dioxide and the like.
The coating according to the present invention is applied by solubilising or suspending the excipients in solvents such as isopropyl alcohol, water, acetone, ethanol, methylene chloride, hydrochloric acid and the like, or mixtures thereof.
In another embodiment, the pharmaceutical composition according to the present invention is in the form of tablets, preferably immediate release tablets.
In another embodiment, the pharmaceutical composition according to the present invention is in the form of tablets which may be coated or uncoated.
In another embodiment, the tablet according to the present invention may be round or oval. The edges of the tablets can be beveled or rounded. In another
embodiment, the tablets are ovoid or round. The tablets according to the invention may be scored.
In another embodiment, the present invention provides a tablet composition comprising Acalabrutinib free base (Equivalent to Acalabrutinib maleate) in the range of about Img to about 500 mg, preferably 50mg to 200mg and more preferably lOOmg.
In another embodiment, the present invention provides a tablet composition comprising Acalabrutinib maleate for the treatment of patients with Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
The invention is further illustrated by the following examples which are provided to be exemplary of the invention and do not limit the scope of the invention. While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
The processing steps involved in manufacturing the tablets were given below:
(i) Acalabrutinib maleate and Silicified Microcrystalline cellulose were sifted separately and blended,
(ii) the blend of step (i) was lubricated with sodium stearyl fumarate stearate, and
(iii) the lubricated granules of step (ii) were compressed into tablets.
Example 2: Tablet composition comprising Acalabrutinib maleate
The processing steps involved in manufacturing the tablets were given below:
(i) Acalabrutinib maleate and lactose monohydrate were sifted separately and blended,
(ii) Povidone was dissolved in purified water to prepare binder solution,
(iii) the blend of step (i) was granulated using the binder solution of step (ii), milled and dried,
(iv) the granules obtained in step (iii) was lubricated with sodium stearyl fumarate, and
(v) the lubricated granules of step (iv) were compressed into tablets. Example 3: Tablet composition comprising Acalabrutinib maleate
The processing steps involved in manufacturing the tablets were given below:
(i) Acalabrutinib maleate and mannitol were sifted separately and blended,
(ii) the blend of step (i) was compacted using roller compaction and milled,
(iii) the milled granules obtained in step (ii) were lubricated with sodium stearyl fumarate, and
(iv) the lubricated granules of step (iii) were compressed into tablets.
The processing steps involved in manufacturing the tablets were given below:
(i) Acalabrutinib maleate and Pregelatinized Starch were sifted separately and blended, (ii) the blend of step (i) was compacted using roller compaction and milled,
(iii) the milled granules obtained in step (ii) were lubricated with sodium stearyl fumarate,
(iv) the lubricated granules of step (iii) were compressed into tablets, and
(v) the tablets of step (iv) were coated with OPADRY coating solution.
Dissolution Data: Table 1 given below provides the comparative dissolution profile of Acalabrutinib maleate 100 mg tablets prepared according to Example 4 with CALQUENCE® 100 mg tablets carried out in 500 ml of 0.1N HC1 as dissolution medium in USP II apparatus (paddle) at 50 rpm. Table 1: Comparative dissolution profile of Acalabrutinib maleate 100 mg tablets prepared according to Example 4 with CALQUENCE® 100 mg tablets
Based on the above data more than 94% release was observed within 15 minutes in both Acalabrutinib maleate 100 mg tablets prepared according to Example 4 and CALQUENCE (Acalabrutinib maleate) 100 mg tablets. Hence, it was concluded that the dissolution profile of Acalabrutinib maleate 100 mg tablets prepared according to Example 4 was comparable with CALQUENCE® (Acalabrutinib maleate) 100 mg tablets.
The Acalabrutinib maleate 100 mg tablets prepared according to Example 4 despite of being free from disintegrating agent exhibited comparable dissolution profile in comparison to reference CALQUENCE® (Acalabrutinib maleate) 100 mg tablets which contain a disintegrating agent.
Stability Data:
Table 2 given below shows the impurity profile of Acalabrutinib maleate 100 mg tablets prepared according to Example 4 of the present invention after storing at 40 ± 2°C/75 ± 5% RH for 2 months.
Table 2: Stability data of Acalabrutinib maleate 100 mg tablets prepared according to Example 4 after storing at 40 ± 2°C/75 ± 5% RH for 2 months.
The above stability study results of the Acalabrutinib maleate 100 mg tablets prepared according to Example 4 of the present invention indicates that, the tablets remain stable for a period of 2 months even after storing at 40 ± 2°C/75 ± 5% RH. Further, the total impurities were found to be within the specified limits.
Claims
1. A tablet composition comprising:
(i) 30-60% w/w of Acalabrutinib maleate,
(ii) 30-60% w/w of one or more diluents,
(iii) 0.5-5% w/w of one or more lubricants, and
(iv) 0-15% w/w of one or more binders, wherein the tablet composition is free of a disintegrant.
2. The tablet composition as claimed in Claim 1, wherein the tablet composition is further coated with a film coating composition.
3. The tablet composition as claimed in Claim 1, wherein one or more diluents are selected from pregelatinized starch, mannitol, microcrystalline cellulose, silicified microcrystalline cellulose and lactose.
4. The tablet composition as claimed in claim 1, wherein the tablet composition comprises:
(i) 30-60% w/w of Acalabrutinib maleate,
(ii) 30-60% w/w of one or more diluents selected from pregelatinized starch, mannitol, microcrystalline cellulose, silicified microcrystalline cellulose and lactose,
(iii) 0.5-5% w/w of one or more lubricants selected from sodium stearyl fumarate and magnesium stearate, and
(iv) 0-15% w/w of one or more binders selected from povidone, hydroxypropyl cellulose and hydroxypropyl methylcellulose.
5. The tablet composition as claimed in claim 1, wherein the tablet composition is prepared by dry granulation, roller compaction, wet granulation, melt granulation, and direct compression.
The tablet composition as claimed in claim 1, wherein the tablet composition is prepared by a process comprising the steps of:
(i) blending Acalabrutinib maleate with one or more diluents,
(ii) granulating the blend of step (i),
(iii) blending the granules of step (ii) with one or more lubricants,
(iv) compressing the blend of step (iii) into tablets, and
(v) coating the tablets obtained in step (iv) with a film coating composition. The tablet composition as claimed in claim 1, wherein the tablet composition is prepared by a process comprising the steps of:
(i) blending Acalabrutinib maleate with one or more diluents,
(ii) lubricating the blend of step (i) with one or more lubricants,
(iii) compressing the blend of step (ii) into tablets, and
(iv) coating the tablets obtained in step (iii) with a film coating composition. A tablet composition consisting of:
(i) 30-60% w/w of Acalabrutinib maleate
(ii) 30-60% w/w of a diluent, and
(iii) 0.5-5% w/w of a lubricant, wherein the tablet composition is free of a disintegrant. A tablet composition consisting of:
(i) 30-60% w/w of Acalabrutinib maleate
(ii) 30-60% w/w of pregelatinized starch,
(iii) 0.5-5% w/w of sodium stearyl fumarate, and
(iv) a film coating over the tablet composition, wherein the tablet composition is free of a disintegrant. The tablet composition as claimed in claim 1, wherein the tablet composition is prepared by a process comprising the steps of:
(i) blending Acalabrutinib maleate with pregelatinized starch,
(ii) granulating the blend of step (i) using roller compaction,
(iii) lubricating the granules of step (ii) with sodium stearyl fumarate,
(iv) compressing the lubricated blend of step (iii) into tablets, and
(v) coating the tablets obtained in step (iv) with a film coating composition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202241059139 | 2022-10-17 | ||
IN202241059139 | 2022-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024084496A1 true WO2024084496A1 (en) | 2024-04-25 |
Family
ID=90737061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2023/050921 WO2024084496A1 (en) | 2022-10-17 | 2023-10-11 | Pharmaceutical compositions comprising acalabrutinib maleate |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024084496A1 (en) |
-
2023
- 2023-10-11 WO PCT/IN2023/050921 patent/WO2024084496A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7727553B2 (en) | Oral preparations with favorable disintegration characteristics | |
KR101699912B1 (en) | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix | |
US9433620B2 (en) | Pharmaceutical compositions of lurasidone | |
CA2942877A1 (en) | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir | |
WO2017208136A1 (en) | Pharmaceutical composition of dapagliflozin co-crystal | |
US11576917B2 (en) | Pharmaceutical compositions comprising Ibrutinib | |
WO2015028875A2 (en) | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir | |
US20140343076A1 (en) | Pharmaceutical compositions of lurasidone | |
US20160199396A1 (en) | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir | |
EP3437645B1 (en) | Film-coated tablet having high chemical stability of active ingredient | |
WO2011158870A1 (en) | Controlled release nucleated tablet | |
US20100055177A1 (en) | Modified release composition of levetiracetam and process for the preparation thereof | |
WO2016012898A1 (en) | Oral pharmaceutical composition of lurasidone | |
WO2024084496A1 (en) | Pharmaceutical compositions comprising acalabrutinib maleate | |
JP7117975B2 (en) | Pharmaceutical composition containing teneligliptin, method for producing pharmaceutical composition containing teneligliptin, tablet containing teneligliptin, and method for producing tablet containing teneligliptin | |
US20080081069A1 (en) | Novel controlled release formulations of divalproex sodium | |
US20200046695A1 (en) | Oral pharmaceutical composition of lurasidone and preparation thereof | |
US20120121722A1 (en) | Atazanavir formulations | |
KR101561345B1 (en) | Controlled-release pharmaceutical composition of propionic acid derivatives | |
WO2022153330A1 (en) | Pharmaceutical compositions comprising acalabrutinib | |
WO2022029798A1 (en) | Pharmaceutical compositions comprising ribociclib | |
KR102488167B1 (en) | Solid composition of pyrrole carboxamide | |
WO2023195022A1 (en) | Stable pharmaceutical compositions comprising erdafitinib | |
JP2021181434A (en) | Water-insoluble polymer-coated granules, formulations containing the same, and methods for manufacturing the same | |
CN111759850A (en) | Pharmaceutical composition of tenofovir oxalate |